Stryker Corporation (SYK): Clark Capital Management Group, Inc. added to its stake +2,478 shares
Clark Capital Management Group, Inc. added to its stake in Stryker Corporation, per its Q4 2024 13F.
- 194K
- Shares reported · +2,478 vs prior quarter
- 0.49%
- Disclosed portfolio weight
- $69.8M
- Reported value
- Holdings as of
- Dec 31, 2024
- Filed
- Feb 14, 2025
What stands out in this filing
- 191,445 shares in Q3 2024, 193,923 now (+1.3% in share count).
- Reported at $69.8M, 0.49% of the portfolio value in this 13F filing.
- 65 other tracked managers reported the same kind of change for Q4 2024.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Feb 2, 2023InsiderOfficer sold ~$211K of SYK shares in the open market
- Jan 15, 2025Congress · 1 personMembers of Congress: 2 purchases
- Jan 31, 2025Insider · 1 personInsiders: 7 sales (~$92.7M)
What came next
- Feb 18, 2025InsiderDirector sold ~$942K of SYK shares in the open market
- Feb 26, 2025CongressDisclosed partial sale of SYK — reported range $15,001 - $50,000
- Feb 28, 2025FDARecall: Monterey AL Implant Inserter; 14/16mm; Catalog 48019120.
- Feb 28, 2025FDARecall: Monterey AL Implant Inserter; 10/12mm; Catalog 48019100.
- Mar 11, 2025FDAFDA device clearance: iBur 3.0mm Diamond Match Head, Distal Bend (8431-107-030D); iBur 3.0mm Precision Round, Distal Bend (8431-009-030); iBur 4.0mm Precision Round, Distal Bend (84…
- Mar 13, 2025CongressDisclosed partial sale of SYK — reported range $50,001 - $100,000
- Mar 21, 2025FDAFDA device clearance: Excelsior XT-27 Microcatheter, Excelsior XT-27 Flex Microcatheter, Excelsior XT-27 Pre-Shaped Microcatheter, Excelsior XT-27 Flex Pre-Shaped Microcatheter
- Mar 21, 2025FDAFDA device clearance: Consolidated Operating Room Equipment (CORE) 2 Console
- Mar 24, 2025FDAFDA device clearance: Sonopet iQ Ultrasonic Aspirator System (5500-050-000)
- Mar 28, 2025FDARecall: Guide Wire with Ruler Tube 3x800 mm DIA; Catalog number/REF: 2351-3080S;
- Mar 28, 2025FDARecall: Guide Wire with Ruler Tube 3x1000 mm DIA; Catalog number/REF: 2351-3100S;
- Apr 7, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
- Apr 8, 2025Congress · 1 personMembers of Congress: 2 sales
- Apr 15, 2025FDAFDA device clearance: OptaBlate Radiofrequency (RF) Generator System
- Apr 17, 2025CongressDisclosed purchase of SYK — reported range $15,001 - $50,000
- May 6, 2025Insider · 1 personInsiders: 6 sales (~$75.4M)
- May 12, 2025InsiderOfficer sold ~$482K of SYK shares in the open market
- May 15, 2025FDAFDA device clearance: OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Single Kit); OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Dual Kit)
- May 21, 2025FDAFDA device clearance: Stryker AlphaVent Knotless SP Biocomposite Anchor
- May 22, 2025FDARecall: Femoral Nail, LEFT T2 GTN 8x300 mm. Catalog Number: 1850-0830S.
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Stryker Corporation
For Stryker Corporation, OQRO holds 13 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SYK page.
How this filing works
Explore the data
Common questions
What does this filing report about Stryker Corporation (SYK) stock?
Clark Capital Management Group, Inc. added to its stake in Stryker Corporation, per its Q4 2024 13F. Now 194K shares, $69.8M reported value, 0.49% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2024. Filed: Feb 14, 2025.
What stands out in this filing?
191,445 shares in Q3 2024, 193,923 now (+1.3% in share count). Reported at $69.8M, 0.49% of the portfolio value in this 13F filing. 65 other tracked managers reported the same kind of change for Q4 2024.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Stryker Corporation recently?
For Stryker Corporation, OQRO holds 13 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 federal contract awards dated in the last 90 days. They are listed on the SYK page.
Does this mean SYK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Stryker Corporation
- House Clerk periodic transaction reportNov 19, 2026
- SEC Form 4Nov 9, 2026
- SEC Form 4Nov 9, 2026
- SEC Form 4Nov 9, 2026
- SEC Form 4Nov 9, 2026
- SEC Form 4Nov 9, 2026
Everything OQRO holds on this company is on its SYK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
